Big studios behind swag-fueled Oscar push






LOS ANGELES (AP) — Giant coffee table books, iPod Shuffles, signed letters from directors, even “Lincoln” turkey roasting pans. That’s just some of the largesse doled out by the studios to voters for awards presented earlier this season — each with the potential to influence the outcome of Hollywood’s most important awards, Sunday night’s Oscars.


Such gifts are strictly forbidden by the Academy of Motion Picture Arts and Sciences. But for studios, the stakes are high, and they’ve been creative in working around the rules to give their movies the best spotlight possible. A best picture win can boost a film’s commercial appeal and solidify relations with big-name actors and directors.






This year, top Oscar contenders “Argo” from Warner Bros. and “Lincoln” from Disney pitted two deep-pocketed rivals against each other in what some say was an unprecedented level of Oscar campaigning. There was even some targeted sniping about the films’ bending of historical facts.


Part of what’s behind the seemingly unrestrained lobbying is that this year, an unusually large number of best picture nominees are also doing well at the box office, giving the studios dry powder for their campaigns.


Six of the nine contenders for the top Oscar have reaped $ 100 million or more in ticket sales domestically, and collectively they’ve earned $ 309 million since the nominations Jan. 10, according to Hollywood.com. This record-setting “Oscar bump” dwarfs the $ 111 million the nine best picture nominees made between the nominations and the awards ceremony last year. It also trumps the season that 2009′s megahit “Avatar” was in the running, when 10 nominees brought in $ 204 million in bump.


That means there’s plenty of reason for studios to keep spending — even to the extent of papering the walls of the popular Beverly Hills restaurant Kate Mantilini with campaign posters, which conveniently tower over diners just a block from the motion picture academy itself.


“I have never seen such an assault in terms of stuff being sent to us,” said Pete Hammond, a member of the Broadcast Film Critics Association, which hosts the Critics Choice Awards, and a columnist for the Hollywood blog Deadline.com.


Hammond is one of several voters for the earlier awards where wins translate into momentum for Oscar hopefuls. They say their mailboxes were swamped with swag this year — all of it an attempt to reach the 5,800 academy members who vote on the Oscars, albeit through indirect means.


From the campaign of Steven Spielberg‘s “Lincoln,” members of the broadcast critics group say they received no less than four coffee table books, an intricately framed DVD for review purposes and even a hand-signed letter from Spielberg himself, thanking them for recognizing the film with so many nominations. Some awards voters also received “Lincoln” turkey roasting pans, according to an industry insider who spoke on the condition of anonymity because the person was not authorized to speak publicly about the matter.


The broadcast critics also received an iPod Shuffle, which retails for $ 49, containing the soundtrack to Universal Pictures’ “Les Miserables,” which is up for music and sound mixing awards.


Several voters said this level of giveaway was unusual, but then again, in recent times, well-funded major studios haven’t been that involved.


In the last two years, the movie industry’s top honor went to The Weinstein Co.’s “The Artist” and “The King’s Speech.” Previous to that, 2009′s winner was “The Hurt Locker,” whose backer Summit Entertainment was just starting to get its “Twilight” mojo and was yet to be flush with cash.


Before that it was Fox Searchlight’s “Slumdog Millionaire” and before that “No Country for Old Men” by Paramount Vantage — both smaller arms of major studios that have smaller marketing budgets than their larger siblings.


This year, the majors are back in the game in a big way. In addition to Warner’s “Argo” and Disney’s “Lincoln,” Sony Pictures is behind “Zero Dark Thirty,” 20th Century Fox is backing “Life of Pi” and Universal is the force behind “Les Miserables.”


While The Weinstein Co.’s “Silver Linings Playbook” is earning boffo business above $ 100 million in ticket sales following co-chairman Harvey Weinstein‘s familiar script of making the most of awards season, it appears that this year, the majors have studied up.


“Nobody ever did it besides Harvey, and now everybody’s done it this year,” said David Poland of MovieCityNews.com, which means more intense campaigning because there’s more money to spend.


One look at the release pattern of “Zero Dark Thirty” and it’s clear that Sony didn’t want to repeat what happened to “The Hurt Locker,” another Kathryn Bigelow-directed war film that despite its best picture win, made just $ 19 million in theaters worldwide. Part of the problem with “Hurt” was that it came out in June and was all but gone from theaters by the time the Oscar nominations rolled around.


Instead, “ZDT” showed in just a handful of theaters in December to qualify for the 2012 Oscars, but burst onto 3,000 theaters the day after the nominations in January, capturing the top spot at the box office that weekend.


“We designed our release campaign to take advantage of key dates in the awards season,” said Sony Pictures spokesman Steve Elzer. “With approximately $ 90 million in box office to date, the film has been a huge critical and commercial success and no matter how we do at the Oscar ceremony on Sunday, we couldn’t be more pleased with the film’s performance.”


Starting small and then going wide after the nominations is the “Playbook” that The Weinstein Co. has followed for years, although company co-chairman Harvey Weinstein denies the pattern.


“There is no playbook, there is no campaigning,” Weinstein said. “I have always said the most important thing is to get people to see the films and everything else is mostly fluff.”


Even films at the tail end of their box-office run are pumping up the volume. “Argo,” which came out in October, was heavily advertised by Warner Bros. ahead of the DVD release this Tuesday. The studio began selling digital downloads two weeks ahead of that. Fox followed a similar strategy for “Life of Pi.”


“Because these films are so strong, all the companies are buying (ads),” said Michael Parker, co-president of Sony Pictures Classics, whose film “Amour” is also up for best picture.


Critic Anne Thompson of Indiewire said this year’s extravagance is due to the fact that big studios have high hopes for their films. Amid her swag pile are “Wreck-It Ralph” plastic fists, a toy bow and arrow from “Brave,” and a printed page of the John Williams score from “Lincoln.”


“The factors here are a) the studios involved and b) big hit movies that had extra money,” she said. “And the fact you have a close race between two big studio movies. They have reason to believe they have a chance to win.”


Gadgets News Headlines – Yahoo! News





Title Post: Big studios behind swag-fueled Oscar push
Url Post: http://www.news.fluser.com/big-studios-behind-swag-fueled-oscar-push/
Link To Post : Big studios behind swag-fueled Oscar push
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

You're Invited to PEOPLE.com's Oscars Party!









02/24/2013 at 08:40 AM EST







From left: Bradley Cooper, Oscar, Jessica Chastain


AFP/Getty; Wireimage; Splash News Online


Oscars host Seth MacFarlane isn't the only one gearing up for Hollywood's biggest night – we are too!

Be a part of the glamour and excitement Sunday at 6 p.m. ET when we roll out the red carpet for our PEOPLE.com VIPs.

Here's what you can expect:
• Tune in to our red carpet preshow for exclusive A-list interviews
• Be the first to see the gorgeous gowns – and make your own best-dressed list
• Download your own Oscars ballot – and make your own Academy Awards picks
• Tweet with our editors at #PeopleOscars
• Take our up-to-the-minute Oscars polls

And come back the next day for so much more ...
• See the night's best dresses from all angles with our 360º slideshow
• Come inside the most exclusive Oscars after-parties
• Relive the most memorable quotes of the show
• Get the scoop on the night's biggest shockers and funniest moments everyone is talking about

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.


Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.


Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.


"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.


Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.


But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.


National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.


"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.


OPTIONS BULLS TARGET GAINS


The spending cuts, if they go ahead, could hit the defense industry particularly hard.


Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.


Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.


"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.


The stock ended up 0.6 percent at $88.12 on Friday.


If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.


General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.


EYES ON GDP DATA, APPLE


The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.


U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.


Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.


Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.


On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.


(Additional reporting by Doris Frankel; Editing by Kenneth Barry)



Read More..

India Ink: In Hyderabad, Anger and Frustration

Srinivas Mahesh, 28, was snacking outside his hostel near the Konark Theater in Dishknagar, his usual hangout in Hyderabad, when he heard a loud explosion Thursday evening. Not long after, he saw smoke filling up the air. Once he realized it was a bomb blast, instead of rushing back to his hostel he resolved to helping the injured.

“I saw disfigured bodies for the first time in my life,” he said. He helped three severely injured people into ambulances and took another injured man by auto to Osmania Hospital.

Mr. Mahesh, who is originally from Kurnool, came to Hyderabad two years ago to do a graduation in engineering from Ashok Institute in Dilsukhnagar. After yesterday’s blasts though, he might have to return home.

“My parents were visiting Hyderabad in 2007, when there were blasts. They had a tough time then,” he said. “After yesterday, they are convinced that this city is cursed and want me home.”

More than 24 hours after two bombs went off near the ever-crowded Dilsukhnagar bus stand, there is palpable frustration and anger in the area. N.Pradeep Reddy, 29, a chartered accountant who lives in Dilsukhnagar, heard the first blast and came to the balcony of his house. Then he saw the second explosion. Aghast, he couldn’t move for several seconds, he said.

Mr. Reddy’s family has been in Hyderabad for 10 years now, but now he is disillusioned with the charm of the city, he said. “No one cares for our lives here – not the politicians, not the media not the police,” he added.

Hyderabad has been the site of numerous explosions in recent years, including two in 2007 attacks that killed dozens of people.

Soon after Thursday’s blasts, the road in front of the Dilsukhnagar bus stand had a median dividing it into two. While traffic was allowed on one side, the other side of the road was cordoned off by the police.

“This is obstructing traffic and adding to the commotion,” said P. Sadanandam, who commutes through the road regularly. “They are not doing this for security, it is just so that the VIPs can visit the blast site and have a photo-op,” he said angrily.

Andhra Pradesh Director General of Police and other senior police officers visited the at blast site today to look for evidence.

All the shops on a two kilometer stretch on the Dilsukhnagar main road were shuttered down all day today. Some security men outside the shops said that this was not due to the bandh, or shutdown, that the Bharatiya Janata Party had called, but because the shop owners were sure that there would be no customers today. They might open on Monday, they said.

Narsing Vennala, 25, sells flowers on the main road. He is one of the only three flower vendors who reopened their shops today. A temple next door needs flowers, he said, and therefore he had to come to work.

His 18-year-old sister is so paranoid about his coming to work a day after the blasts that she keeps calling him every half-an-hour to check if he is alright.  Mr Vennala walks home at 11 p.m. every night, and he plans to do the same even today.

“Whatever had to happen, happened,” he said. “Now how long can we stay hungry and not earn because of that?”

“Bharat mata ki jai,” (Victory for mother India) was loudly shouted by a bunch of residents. They said that was their answer to those that were against peace in the country.  There was also some anti-Pakistan sloganeering.

One resident estimated that there were 500 to 600 educational institutions in Dilsukhnagar. They have offerings ranging from short-term computer courses to three-year degrees. Thousands of students, from smaller towns and neighboring districts, live in hostels around their respective institutions. Many of them were on the streets yesterday to help the injured.

While some students don’t see any option but to stay in the city, others, like Mr. Mahesh, are packing their bags.

“I have to go home, even if I don’t like to,” he said “My family will be worried every day I stay in Hyderabad.”

Read More..

Biggest Loser's Francelina Morillo: Jeff Nichols and I 'Have Something Special'






The Biggest Loser










02/23/2013 at 08:30 AM EST







Francelina Morillo and Jeff Nichols


Trae Patton/NBC (2)


Francelina Morillo may have lost the chance to win the title of Biggest Loser, but she has found love.

"We have something special," Morillo said Tuesday about falling for fellow constant Jeff Nichols while on the ranch. "I have found a bond with him that I haven't had with anyone else. It's like a mirror when I look at him."

Morillo, 26, and Nichols, 25, both lost their fathers while in their teens and bonded in the gym as they began to shed their weight – and emotional baggage.

"You get to see the person at their worst and you see them blossom and grow and become this better version of themselves. You learn to appreciate and admire them in a different way," Morillo says of her time with Nichols on the show.

But the couple was temporarily separated when Morillo was sent home for losing the least amount of weight in the episode that aired last Monday.

"I knew I had gathered the tools in there that I needed to survive in the real world," Morillo says of her tearful sendoff. "I've learned I can do this for the rest of my life and that I can keep the weight off – which is my ultimate goal."

Morillo returned home to New York but soon joined Nichols in Chicago. Now the couple are motivating each other to continue to lose weight.

"We balance each other out. He has the nutrition down pat and I am an exercise junky," Morillo says about working out with Nichols, whose status as a finalist or contender for the at-home prize has yet to be revealed. "It's just so much easier when you have the support of somebody else that knows exactly what you're going through."

Morillo arrived at the ranch weighing 267 lbs., after having lost 100 lbs. at home on her own, and now continues to lose weight by working with a trainer, spending two hours a day on the stairmill and monitoring her portion sizes.

"I was eating a lot of healthy stuff, but I was binging on everything," says Morillo, who used to eat large amounts of apples or oatmeal throughout the day. "If you have too much of good thing, it's also bad. Now I'm all about portion size."

With her eye on the $100,000 at-home prize, Morillo is also looking forward to applying to medical school and eventually fulfilling her dream to become a doctor.

"The new me is positive, outgoing, always smiling and wants the best for me," she says. "I've learned the best way to do that is to surround yourself with positive energy, positive people. That's who I am, and that’s what I radiate from now on."

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Stock futures rise after HP earnings, German data

NEW YORK (Reuters) - Stock index futures rose on Friday, indicating the S&P 500 may halt a two-day losing skid, boosted by positive economic data from Europe and better-than-expected earnings from Hewlett-Packard.


The S&P 500 <.spx> has dropped 1.9 percent over the past two sessions, its worst two-day drop since early November, putting the index on pace for its first weekly decline of the year. The retreat was triggered by minutes from the Federal Reserve's January meeting released earlier in the week which suggested stimulus measures may end earlier than thought.


Still, the index is up more than 5 percent for the year and has held the 1,500 support level.


Hewlett-Packard Co climbed 4.7 percent to $17.90 in premarket trading after the No. 1 personal computer maker's quarterly revenue and forecasts beat Wall Street expectations as it continued to cut costs under CEO Meg Whitman's turnaround plan.


The German Ifo business climate indicator for February rose to 107.4, its best one-month rise in more than two years, boosting optimism after Thursday's disappointing PMI data stoked concerns over the euro zone economy.


S&P 500 futures rose 6.4 points and were above fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures gained 28 points, and Nasdaq 100 futures added 10.5 points.


Insurer American International Group Inc reported fourth-quarter results that beat analysts' expectations, although Chief Executive Robert Benmosche said some employee bonuses will be smaller this year because the company did not meet all of its performance targets. Shares advanced 3.8 percent to $38.68 in premarket trading.


Marvell Technology Group Ltd rose 4.5 percent to $9.90 in premarket trade after the chipmaker forecast results this quarter that were largely above analysts' expectations as it gained market share in the hard-disk drive and flash-storage businesses.


Fellow chipmaker Texas Instruments Inc raised its quarterly dividend by a third and said it would buy back an additional $5 billion in stock.


According to Thomson Reuters data through Thursday morning, of 427 companies in the S&P 500 that have reported results, 69.3 percent have exceeded analysts' expectations, compared with a 62 percent average since 1994 and 65 percent over the past four quarters.


Fourth-quarter earnings for S&P 500 companies are estimated to have risen 5.9 percent, according to the data, above a 1.9 percent forecast at the start of the earnings season.


European shares advanced after the better-than-expected German survey, with the pan-European FTSEurofirst 300 index <.fteu3> up 1.1 percent. <.eu/>


Asian shares recouped some of the previous session's steep falls as investors reassessed concerns that the Federal Reserve may end its ultra-soft monetary policy earlier than expected, but weak U.S. and European data capped Friday's recovery.


(Editing by Bernadette Baum)



Read More..

Josh Brolin & Diane Lane: Inside Their Up-and-Down Marriage















02/22/2013 at 07:30 AM EST







Diane Lane and Josh Brolin


Steve Granitz/Wireimage


Josh Brolin and Diane Lane's eight-year marriage is ending in divorce, but the road wasn't always rocky for the occasionally tumultuous pair.

"We're very similar in that celebrity is not a necessity," Brolin, 45, told PEOPLE in 2003, after meeting his soon-to-be-bride, 48, the previous year through stepmom Barbra Streisand. "Everything is easy."

The simplicity seemingly continued for Brolin and his beauty, who wed the following year in a ceremony at the actor's central California ranch.

Though there was a bit of a rocky start to their marriage, the pair got on track in 2005. As Lane told PEOPLE at the time, "I feel much better having a strong man with me who makes me feel embraced and secure. It's wonderful."

With her first marriage to actor Christopher Lambert behind her, Lane went on to say, "I wasn't going to go relationship shopping with my young daughter. I didn't want her to get attached to something that wasn't going to last."

In 2008, Lane praised Brolin, telling Redbook: "It's just invigorating to be around him. Josh completes me because I'm so attracted to his otherness."

On Thursday, reps confirmed the pair split, with a source telling PEOPLE, "They've been separated for several months. This was a hard decision for both of them to make. They were together for 11 years, the relationship just ran its course."

News of the breakup came almost two months after Brolin was held for public intoxication just before midnight on New Year's Eve 2013. Released without charge, the actor was spotted without his wedding ring the following day, donning sunglasses, in Venice, Calif., where he seemed unfazed by the trouble as he ate with a male friend at Sauce on Hampton.

Read More..

Flu shot doing poor job of protecting older people


ATLANTA (AP) — It turns out this year's flu shot is doing a startlingly dismal job of protecting older people, the most vulnerable age group.


The vaccine is proving only 9 percent effective in those 65 and older against the harsh strain of the flu that is predominant this season, the Centers for Disease Control and Prevention said Thursday.


Health officials are baffled as to why this is so. But the findings help explain why so many older people have been hospitalized with the flu this year.


Despite the findings, the CDC stood by its recommendation that everyone over 6 months get flu shots, the elderly included, because some protection is better than none, and because those who are vaccinated and still get sick may suffer less severe symptoms.


"Year in and year out, the vaccine is the best protection we have," said CDC flu expert Dr. Joseph Bresee.


Overall, across the age groups studied, the vaccine's effectiveness was found to be a moderate 56 percent, which means those who got a shot have a 56 percent lower chance of winding up at the doctor with the flu. That is somewhat worse than what has been seen in other years.


For those 65 and older, the vaccine was only 27 percent effective against the three strains it is designed to protect against, the worst level in about a decade. It did a particularly poor job against the tough strain that is causing more than three-quarters of the illnesses this year.


It is well known that flu vaccine tends to protect younger people better than older ones. Elderly people have weaker immune systems that don't respond as well to flu shots, and they are more vulnerable to the illness and its complications, including pneumonia.


But health officials said they don't know why this year's vaccine did so poorly in that age group.


One theory, as yet unproven, is that older people's immune systems were accustomed to strains from the last two years and had more trouble switching gears to handle this year's different, harsh strain.


The preliminary data for senior citizens is less than definitive. It is based on fewer than 300 people scattered among five states.


But it will no doubt surprise many people that the effectiveness is that low, said Michael Osterholm, a University of Minnesota infectious-disease expert who has tried to draw attention to the need for a more effective flu vaccine.


Among infectious diseases, flu is considered one of the nation's leading killers. On average, about 24,000 Americans die each flu season, according to the CDC.


This flu season started in early December, a month earlier than usual, and peaked by the end of year. Hospitalization rates for people 65 and older have been some of the highest in a decade, at 146 per 100,000 people.


Flu viruses tend to mutate more quickly than others, so a new vaccine is formulated each year to target the strains expected to be the major threats. CDC officials have said that in formulating this year's vaccine, scientists accurately anticipated the strains that are circulating this season.


Because of the guesswork involved, scientists tend to set a lower bar for flu vaccine. While childhood vaccines against diseases like measles are expected to be 90 or 95 percent effective, a flu vaccine that's 60 to 70 percent effective in the U.S. is considered pretty good. By that standard, this year's vaccine is OK.


For senior citizens, a flu vaccine is considered pretty good if it's in the 30 to 40 percent range, said Dr. Arnold Monto, a University of Michigan flu expert.


A high-dose version of the flu shot was recently made available for those 65 and older, but the new study was too small to show whether that has made a difference.


The CDC estimates are based on about 2,700 people who got sick in December and January. The researchers traced back to see who had gotten shots and who hadn't. An earlier, smaller study put the vaccine's overall effectiveness at 62 percent, but other factors that might have influenced that figure weren't taken into account.


The CDC's Bresee said there is a danger in providing preliminary results because it may result in people doubting — or skipping — flu shots. But the figures were released to warn older people who got shots that they may still get sick and shouldn't ignore any serious flu-like symptoms, he said.


___


Online:


CDC report: http://www.cdc.gov/mmwr


Read More..